HPLC–MS/MS Method for the Determination of Cytarabine in Human Plasma
- 14 July 2011
- journal article
- clinical trial
- Published by Taylor & Francis in Bioanalysis
- Vol. 3 (14), 1603-1611
- https://doi.org/10.4155/bio.11.140
Abstract
Cytarabine is an anti-tumor drug that is currently under investigation for treatment in combination with other anticancer drugs for the chemotherapy of leukemia. The quantitative determination of cytarabine in plasma is challenging due to the required sensitivity, its in vitro instability and the presence of an isobaric endogenous compound, cytidine. Owing to the polarity of cytarabine, conventional chromatography cannot provide adequate separation of the analyte and the interfering compounds. A few analytical methods have been reported for the determination of cytarabine in plasma, but their sensitivity was not sufficient since most of these methods apply spectrophotometric detection. In this article, an LC-MS/MS method is described for the determination of cytarabine in human plasma down to the sub ng/ml level. To prevent conversion of cytarabine by cytidine deaminase, whole blood samples were stabilized with tetrahydrouridine directly after the collection of whole blood at the clinical site. Cation-exchange SPE was employed to extract cytarabine from 50 µl human plasma. UHPLC on high strength silica T3 column (100 × 2.1 mm × 1.8 µm) was applied to achieve adequate separation of cytarabine from cytidine within a reasonable run time of 5 min. A triple quad mass spectrometer equipped with an ESI source was used for detection. The method was linear over the concentration ranges of 0.500-500 ng/ml. The intra- and inter-day relative standard deviation (precision) as well as the bias (accuracy) were well below 15%. In the presence of tetrahydrouridine, cytarabine was sufficiently stable under all relevant conditions. The method was successfully applied to support a clinical pharmacokinetic study with a low dose of cytarabine.Keywords
This publication has 9 references indexed in Scilit:
- HPLC method development and validation for simultaneous detection of Arabinoside-C and doxorubicinToxicology Mechanisms and Methods, 2010
- High-performance liquid chromatography/tandem mass spectrometry method for the simultaneous determination of cytarabine and its valyl prodrug valcytarabine in rat plasmaJournal of Chromatography B, 2008
- A mixed-mode liquid chromatography-tandem mass spectrometric method for the determination of cytarabine in mouse plasmaJournal of Chromatography B, 2007
- Supercritical Fluid Chromatography and High-Performance Liquid Chromatography/Tandem Mass Spectrometric Methods for the Determination of Cytarabine in Mouse PlasmaAnalytical Chemistry, 2007
- Porous graphitic carbon chromatography/tandem mass spectrometric determination of cytarabine in mouse plasmaRapid Communications in Mass Spectrometry, 2007
- An ion‐pairing liquid chromatography/tandem mass spectrometric method for the determination of cytarabine in mouse plasmaRapid Communications in Mass Spectrometry, 2007
- Cytarabine release from comatrices of albumin microspheres in a poly(lactide–co-glycolide) film: in vitro and in vivo studiesEuropean Journal of Pharmaceutics and Biopharmaceutics, 2003
- 1-β-arabinofuranosylcytosine in therapy of leukemia: Preclinical and clinical overviewPharmacology & Therapeutics, 1992
- Plasma and cerebrospinal fluid pharmacokinetics of cytosine arabinoside in dogsCancer Chemotherapy and Pharmacology, 1991